Jove
Visualize
Contact Us

Related Concept Videos

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Magnetic Resonance Imaging Surveillance Detects Early-stage Pancreatic Cancer In Carriers Of A P16-leiden Mutation.
  1. Home
  3. Magnetic Resonance Imaging Surveillance Detects Early-stage Pancreatic Cancer In Carriers Of A P16-leiden Mutation.

Related Experiment Video

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation.

Hans F A Vasen1, Martin Wasser, Anneke van Mil

  • 1Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands. hfavasen@stoet.nl

Gastroenterology
|December 7, 2010

View abstract on PubMed

Summary
This summary is machine-generated.

Annual MRI/MRCP surveillance in individuals with p16-Leiden mutations detected pancreatic cancer early. While surveillance improved resectability, these aggressive tumors still pose a significant risk.

More Related Videos

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
06:57

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Published on: April 7, 2018

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model
06:24

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model

Published on: April 18, 2015

Related Experiment Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
06:57

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Published on: April 7, 2018

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model
06:24

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model

Published on: April 18, 2015

Area of Science:

  • Oncology
  • Gastroenterology
  • Medical Imaging

Background:

  • Individuals with germline p16-Leiden mutations have a 15-20% lifetime risk of pancreatic cancer.
  • Early detection and treatment are crucial for improving outcomes in high-risk pancreatic cancer groups.

Purpose of the Study:

  • To assess the feasibility of early pancreatic cancer detection in p16-Leiden mutation carriers.
  • To investigate the outcomes of patients with neoplastic lesions identified during surveillance.

Main Methods:

  • 79 individuals with p16-Leiden mutations underwent annual surveillance using MRI and MRCP.
  • Neoplastic lesions identified were managed with surgery or intensive follow-up.
  • Follow-up MRI/MRCP was performed within 2-4 months for suspected lesions.

Main Results:

  • Pancreatic cancer was diagnosed in 7 patients (9%) after a median follow-up of 4 years.
  • All 7 diagnosed tumors were resectable; 5 underwent surgery.
  • Duct ectasias, potential precursor lesions, were found in 9 individuals (11%).

Conclusions:

  • MRI/MRCP effectively detects small pancreatic tumors and duct ectasias in high-risk individuals.
  • Surveillance enhances tumor resectability rates in this cohort.
  • P16-Leiden mutation carriers tend to develop aggressive pancreatic tumors.